Here are the 10-K annual reports from 4D Molecular Therapeutics, Inc. (FDMT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow FDMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FDMT filings page.
4D Molecular Therapeutics describes a late-stage gene therapy pipeline focused on retinal and lung diseases. Lead candidate 4D-150, for wet age-related macular degeneration and diabetic macular edema, is in global Phase 3 trials with RMAT and PRIME designations and strong early data on reducing anti-VEGF injection burden.
The company is also advancing 4D-710 for cystic fibrosis lung disease, showing durable CFTR expression and early clinical activity in the AEROW Phase 1/2 trial, with Phase 2 dosing selected. As of June 30, 2025, non-affiliate equity was valued at $166,461,070, and as of March 16, 2026, 51,051,487 common shares were outstanding, with an additional 16,935,665 shares issuable upon exercise of pre-funded warrants.